{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:25:35Z","timestamp":1790810735484,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HHLA2 is a recently discovered member of the B7-family of immune checkpoint molecules with limited expression in normal tissues but overexpression in several types of cancer. The aim was to determine the expression, prevalence and biological relevance of HHLA2 protein expression in two closely related human cancer types, namely pancreatic cancer and ampullary cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HHLA2 expression levels were retrospectively determined by immunohistochemistry in tissue micro-arrays of surgically resected tumours of 122 pancreatic cancer patients and 72 patients with ampullary cancer of the pancreato-biliary subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HHLA2 was expressed at variable levels by tumour cells in 67% of pancreatic tumours and 93% of ampullary tumours. In the combined cohort high tumoural HHLA2 expression levels were significantly associated with delayed cancer recurrence and improved post-operative cancer-specific survival. The association of HHLA2 expression with cancer-specific survival and recurrence was statistically significant for the pancreatic cancer subgroup while a similar trend was found for the ampullary cancer subgroup. In multivariable analysis together with clinicopathologic characteristics, higher HHLA2 expression was an independent predictor of cancer-specific survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The wide expression of HHLA2 in tumour cells and its association with cancer recurrence and patient survival suggest that HHLA2 represents a relevant immune checkpoint molecule in pancreatic and ampullary cancers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-020-0755-4","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T19:06:54Z","timestamp":1582052814000},"page":"1211-1218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis"],"prefix":"10.1038","volume":"122","author":[{"given":"Patrick P. C.","family":"Boor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostandinos","family":"Sideras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Biermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hosein Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris J. M.","family":"Levink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Mancham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Erler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper H.","family":"van Eijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco J.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Sprengers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap","family":"Kwekkeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"755_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"755_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","volume":"388","author":"T Kamisawa","year":"2016","unstructured":"Kamisawa, T., Wood, L. D., Itoi, T. & Takaori, K. Pancreatic cancer. Lancet. 388, 73\u201385 (2016).","journal-title":"Lancet."},{"key":"755_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4251\/wjgo.v9.i10.407","volume":"9","author":"MD Chandrasegaram","year":"2017","unstructured":"Chandrasegaram, M. D., Gill, A. J., Samra, J., Price, T., Chen, J., Fawcett, J. et al. Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World J. Gastrointest. Oncol. 9, 407\u2013415 (2017).","journal-title":"World J. Gastrointest. Oncol."},{"key":"755_CR4","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1200\/JCO.2012.46.8868","volume":"31","author":"DK Chang","year":"2013","unstructured":"Chang, D. K., Jamieson, N. B., Johns, A. L., Scarlett, C. J., Pajic, M., Chou, A. et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J. Clin. Oncol. 31, 1348\u20131356 (2013).","journal-title":"J. Clin. Oncol."},{"key":"755_CR5","doi-asserted-by":"crossref","unstructured":"Ahn D. H., Bekaii-Saab T. Ampullary cancer: an overview. Am. Soc. Clin. Oncol. Educ. Book. 112\u2013115 (2014).","DOI":"10.14694\/EdBook_AM.2014.34.112"},{"key":"755_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.ccell.2015.12.012","volume":"29","author":"S Yachida","year":"2016","unstructured":"Yachida, S., Wood, L. D., Suzuki, M., Takai, E., Totoki, Y., Kato, M. et al. Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. Cancer Cell. 29, 229\u2013240 (2016).","journal-title":"Cancer Cell."},{"key":"755_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817\u20131825 (2011).","journal-title":"N. Engl. J. Med."},{"key":"755_CR8","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691\u20131703 (2013).","journal-title":"N. Engl. J. Med."},{"key":"755_CR9","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","volume":"27","author":"MJ Overman","year":"2009","unstructured":"Overman, M. J., Varadhachary, G. R., Kopetz, S., Adinin, R., Lin, E., Morris, J. S. et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J. Clin. Oncol. 27, 2598\u20132603 (2009).","journal-title":"J. Clin. Oncol."},{"key":"755_CR10","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science. 359, 1350\u20131355 (2018).","journal-title":"Science."},{"key":"755_CR11","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S. et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33, 828\u2013833 (2010).","journal-title":"J. Immunother."},{"key":"755_CR12","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"755_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357, 409\u2013413 (2017).","journal-title":"Science."},{"key":"755_CR14","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-17-3099","volume":"24","author":"ZI Hu","year":"2018","unstructured":"Hu, Z. I., Shia, J., Stadler, Z. K., Varghese, A. M., Capanu, M., Salo-Mullen, E. et al. Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin. Cancer Res. 24, 1326\u20131336 (2018).","journal-title":"Clin. Cancer Res."},{"key":"755_CR15","doi-asserted-by":"publisher","first-page":"9879","DOI":"10.1073\/pnas.1303524110","volume":"110","author":"R Zhao","year":"2013","unstructured":"Zhao, R., Chinai, J. M., Buhl, S., Scandiuzzi, L., Ray, A., Jeon, H. et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. Proc Natl Acad Sci USA 110, 9879\u20139884 (2013).","journal-title":"Proc Natl Acad Sci USA"},{"key":"755_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3043","volume":"4","author":"Y Zhu","year":"2013","unstructured":"Zhu, Y., Yao, S., Iliopoulou, B. P., Han, X., Augustine, M. M., Xu, H. et al. B7-H5 costimulates human T cells via CD28H. Nat. Commun. 4, 2043 (2013).","journal-title":"Nat. Commun."},{"key":"755_CR17","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1158\/1078-0432.CCR-17-2924","volume":"24","author":"H Cheng","year":"2018","unstructured":"Cheng, H., Borczuk, A., Janakiram, M., Ren, X., Lin, J., Assal, A. et al. Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1-negative human lung cancers. Clin. Cancer Res. 24, 1954\u20131964 (2018).","journal-title":"Clin. Cancer Res."},{"key":"755_CR18","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1158\/1078-0432.CCR-14-2658","volume":"21","author":"Y Xiao","year":"2015","unstructured":"Xiao, Y. & Freeman, G. J. A new B7:CD28 family checkpoint target for cancer immunotherapy: HHLA2. Clin. Cancer Res. 21, 2201\u20132203 (2015).","journal-title":"Clin. Cancer Res."},{"key":"755_CR19","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1158\/1078-0432.CCR-14-1495","volume":"21","author":"M Janakiram","year":"2015","unstructured":"Janakiram, M., Chinai, J. M., Fineberg, S., Fiser, A., Montagna, C., Medavarapu, R. et al. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. Clin. Cancer Res. 21, 2359\u20132366 (2015).","journal-title":"Clin. Cancer Res."},{"key":"755_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/srep30093","volume":"6","author":"P Koirala","year":"2016","unstructured":"Koirala, P., Roth, M. E., Gill, J., Piperdi, S., Chinai, J. M., Geller, D. S. et al. Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. Sci. Rep. 6, 30093 (2016).","journal-title":"Sci. Rep."},{"key":"755_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/1078-0432.CCR-15-3071","volume":"23","author":"H Cheng","year":"2017","unstructured":"Cheng, H., Janakiram, M., Borczuk, A., Lin, J., Qiu, W., Liu, H. et al. HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin. Cancer Res. 23, 825\u2013832 (2017).","journal-title":"Clin. Cancer Res."},{"key":"755_CR22","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/OTT.S160493","volume":"11","author":"Z Zhu","year":"2018","unstructured":"Zhu, Z. & Dong, W. Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma. Onco Targets Ther. 11, 1563\u20131570 (2018).","journal-title":"Onco Targets Ther."},{"key":"755_CR23","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1159\/000495887","volume":"141","author":"G Lin","year":"2019","unstructured":"Lin, G., Ye, H., Wang, J., Chen, S., Chen, X. & Zhang, C. Immune checkpoint human endogenous Retrovirus-H long terminal repeat-associating protein 2 is upregulated and independently predicts unfavorable prognosis in bladder urothelial carcinoma. Nephron 141, 256\u2013264 (2019).","journal-title":"Nephron"},{"key":"755_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/jmedgenet-2018-105454","volume":"56","author":"D Chen","year":"2019","unstructured":"Chen, D., Chen, W., Xu, Y., Zhu, M., Xiao, Y., Shen, Y. et al. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. J. Med. Genet. 56, 43\u201349 (2019).","journal-title":"J. Med. Genet."},{"issue":"Suppl 3","key":"755_CR25","doi-asserted-by":"publisher","first-page":"S1574","DOI":"10.1245\/s10434-014-4293-2","volume":"22","author":"JT Byers","year":"2015","unstructured":"Byers, J. T., Paniccia, A., Kaplan, J., Koenig, M., Kahn, N., Wilson, L. et al. Expression of the novel costimulatory molecule B7-H5 in pancreatic cancer. Ann. Surg Oncol. 22(Suppl 3), S1574\u2013S1579 (2015).","journal-title":"Ann. Surg Oncol."},{"key":"755_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.canlet.2018.11.007","volume":"442","author":"H Yan","year":"2019","unstructured":"Yan, H., Qiu, W., Koehne de Gonzalez, A. K., Wei, J. S., Tu, M., Xi, C. H. et al. HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival. Cancer Lett. 442, 333\u2013340 (2019).","journal-title":"Cancer Lett."},{"key":"755_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ijc.30760","volume":"141","author":"K Sideras","year":"2017","unstructured":"Sideras, K., Biermann, K., Yap, K., Mancham, S., Boor, P. P. C., Hansen, B. E. et al. Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. Int. J. Cancer 141, 572\u2013582 (2017).","journal-title":"Int. J. Cancer"},{"key":"755_CR28","doi-asserted-by":"publisher","first-page":"e1273309","DOI":"10.1080\/2162402X.2016.1273309","volume":"6","author":"K Sideras","year":"2017","unstructured":"Sideras, K., Biermann, K., Verheij, J., Takkenberg, B. R., Mancham, S., Hansen, B. E. et al. PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 6, e1273309 (2017).","journal-title":"Oncoimmunology."},{"issue":"18 Pt 1","key":"755_CR29","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-07-1030","volume":"13","author":"X Zang","year":"2007","unstructured":"Zang, X. & Allison, J. P. The B7 family and cancer therapy: costimulation and coinhibition. Clin. Cancer Res. 13(18 Pt 1), 5271\u20135279 (2007).","journal-title":"Clin. Cancer Res."},{"key":"755_CR30","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/annonc\/mdu452","volume":"25","author":"D Massi","year":"2014","unstructured":"Massi, D., Brusa, D., Merelli, B., Ciano, M., Audrito, V., Serra, S. et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann. Oncol. 25, 2433\u20132442 (2014).","journal-title":"Ann. Oncol."},{"key":"755_CR31","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","volume":"25","author":"TK Choueiri","year":"2014","unstructured":"Choueiri, T. K., Fay, A. P., Gray, K. P., Callea, M., Ho, T. H., Albiges, L. et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol. 25, 2178\u20132184 (2014).","journal-title":"Ann. Oncol."},{"key":"755_CR32","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra37 (2012).","journal-title":"Sci. Transl. Med."},{"key":"755_CR33","doi-asserted-by":"publisher","first-page":"e1002729","DOI":"10.1080\/2162402X.2014.1002729","volume":"4","author":"F Bertucci","year":"2015","unstructured":"Bertucci, F., Finetti, P., Mamessier, E., Pantaleo, M. A., Astolfi, A., Ostrowski, J. et al. PDL1 expression is an independent prognostic factor in localized GIST. Oncoimmunology 4, e1002729 (2015).","journal-title":"Oncoimmunology"},{"key":"755_CR34","doi-asserted-by":"publisher","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger, S., Spaapen, R. M., Zha, Y., Williams, J., Meng, Y., Ha, T. T. et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5, 200ra116 (2013).","journal-title":"Sci. Transl. Med."},{"key":"755_CR35","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1084\/jem.20161462","volume":"213","author":"A Ribas","year":"2016","unstructured":"Ribas, A. & Hu-Lieskovan, S. What does PD-L1 positive or negative mean? J. Exp. Med. 213, 2835\u20132840 (2016).","journal-title":"J. Exp. Med."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0755-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0755-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-020-0755-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:07:34Z","timestamp":1684602454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-0755-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,4,14]]}},"alternative-id":["755"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-0755-4","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]},"assertion":[{"value":"19 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the medical ethical Committee of Erasmus MC, Rotterdam, and study was performed in accordance with the Declaration of Helsinki. Erasmus MC Medical Ethical Committee waived the need for informed patient consent because residual resection tissue was used, and patients did not receive any study treatment (MEC-2016-199).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was funded by Erasmus MC, Rotterdam.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}